This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
As data and digital technology become vital to every aspect of lifesciences, the industry is increasingly looking beyond biologists, chemists, and doctors to drive its drug development – and finding that technology has a chief role to play in the future of medicine. on Big data: astronomical or genomical? ,
I recently had the pleasure of attending the PING Conference 2022 , which had the tagline of ‘The Golden Age for LifeSciences Innovation’. Aspirations for the UK in lifesciences. So, with all that said, are we really in a golden age for UK lifesciences? Reducing complexity across the NHS.
New advances in heart failure genomics are helping to address this challenge. Experts from Servier and Genuity Science recently spoke on a webinar about using genomics data to drive drug development in heart failure and identify new targets for novel therapeutics. Watch this on-demand webinar to hear from these experts.
They performed ultra-deep genomic profiling of normal lung tissue samples and tissues exposed to PM (both human and mouse tissues) and examined the effects of the PM on tumor promotion in mouse lung cancer models. The researchers performed a combination of human and animal experiments to examine a potential link between PM 2.5
About Bayer Bayer is a global enterprise with core competencies in the lifescience fields of health care and nutrition. The company’s approach to research prioritizes targets and pathways with the potential to impact the way that cancer is treated.
The power of leveraging clinical data to decipher disease mechanisms and fuel drug discovery has rapidly grown in the era of genomics and personalized medicine. Biobanks are used for the coordination of high-yield patient sample collection. Generation of strong research dataset cohorts must begin with high-quality clinical samples.
We organize all of the trending information in your field so you don't have to. Join 21,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content